BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has announced a strategic co-marketing and co-promotion agreement with Waters to enhance biotherapeutic characterization and development processes. The partnership combines Bio-Techne's MauriceFlex™ System for charge separation with Waters' BioAccord™ LC-MS System for liquid chromatography mass spectrometry.

The collaboration has already yielded joint activities in late 2024, including an application note, webinar, and presentations at major conferences such as CASSS MS, Festival of Biologics, and PEGS EU. Scientists from both companies are currently working on analyzing additional biomolecule classes, with plans to showcase results at upcoming scientific conferences through various formats including application notes and webinars.

Positive

• Strategic partnership with Waters enhances product offering in biotherapeutic characterization
• Expansion of market reach through combined expertise and technologies
• Active collaboration demonstrated through multiple scientific presentations and publications

Negative

• None.

Insights

Market Research Analyst

The co-marketing agreement between Bio-Techne and Waters represents an incremental business development rather than a substantial financial catalyst. While the partnership combines Bio-Techne's MauriceFlex™ System with Waters' BioAccord™ LC-MS System, creating potential workflow optimizations in biotherapeutic characterization, this is primarily a marketing collaboration without immediate revenue implications.

The key value proposition lies in the potential for future market penetration through combined sales efforts and technical integration. However, the announcement focuses on past marketing activities (conferences, webinars) and future promotional plans rather than concrete business metrics or financial commitments. For Bio-Techne, with a market cap of $11.3 billion, this type of partnership, while strategically sound for product visibility, is unlikely to materially impact near-term financial performance.

The collaboration may enhance Bio-Techne's competitive position in the biotherapeutic characterization space by offering more comprehensive solutions to customers, but the impact will likely be gradual and dependent on successful execution of joint marketing initiatives.

Biotech Industry Expert

From a technical perspective, the integration of Bio-Techne's charge separation technology with Waters' mass spectrometry capabilities addresses a significant workflow challenge in biotherapeutic development. The MauriceFlex™ System's charge variant analysis capabilities, when combined with the BioAccord™ LC-MS System, could potentially reduce analysis time and improve characterization accuracy for complex biologics.

However, this collaboration appears focused on marketing synergies rather than technological innovation or product development. The emphasis on application notes, webinars and conference presentations suggests a promotional strategy aimed at increasing market awareness rather than developing new integrated solutions. While valuable for customer education and market visibility, such initiatives typically yield modest returns in the highly competitive biotech tools sector.

MINNEAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex™ System) and liquid chromatography mass spectrometry (BioAccord™ LC-MS System from Waters) to deliver innovative solutions that optimize workflows, improve precision, and accelerate development timelines.

Scientists and commercial team members from both companies participated in several joint activities in October and November 2024, including the publication of an application note, a webinar, poster presentations, and talks at key conferences including CASSS MS, Festival of Biologics and PEGS EU, and in-person talks at two Bio-Techne User Group Meetings in Boston and San Diego. Moving forward, application scientists from both companies are working on the analysis of additional classes of biomolecules and plan to exhibit the joint results in a poster at upcoming scientific conferences. This work will guide application notes, webinars, and presentations at upcoming Bio-Techne User Group Meetings to co-market each company's advanced biotherapeutic characterization and development process capabilities.

"We are thrilled to see how these new workflows are accelerating biotherapeutic characterization in biopharma labs," said Will Geist, President of the Protein Sciences Segment at Bio-Techne. "Our goal is to continue offering innovative solutions that empower scientists, streamline workflows, and help bring life-saving therapies to market faster."

Explore Bio-Techne's automated biotherapeutic characterization platforms here.

Learn about Waters innovative analytical solutions here.

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

BioAccord is a trademark of Waters Technologies Corporation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-biotherapeutic-characterization-strategic-co-marketing-and-co-promotion-agreement-302335808.html

SOURCE Bio-Techne Corporation

FAQ

What is the purpose of Bio-Techne's (TECH) partnership with Waters ?

The partnership aims to expand biotherapeutic characterization capabilities by combining Bio-Techne's MauriceFlex™ System for charge separation with Waters' BioAccord™ LC-MS System for liquid chromatography mass spectrometry.

What joint activities have Bio-Techne (TECH) and Waters conducted in 2024?

In October and November 2024, they published an application note, conducted a webinar, and gave presentations at conferences including CASSS MS, Festival of Biologics, and PEGS EU, plus Bio-Techne User Group Meetings in Boston and San Diego.

How will the Bio-Techne (TECH) and Waters partnership benefit biotherapeutic development?

The partnership aims to optimize workflows, improve precision, and accelerate development timelines in biotherapeutic characterization and development processes.

What are the future plans for the Bio-Techne (TECH) and Waters collaboration?

Application scientists from both companies are working on analyzing additional biomolecule classes and plan to present results at upcoming scientific conferences through posters, application notes, and webinars.